571 research outputs found
Bonding of self-etch and total-etch adhesives to carious dentin
published_or_final_versio
Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
BACKGROUND: Data on the performance of standardized short-course directly observed treatment (DOTS) of tuberculosis (TB) in areas with high levels of drug resistance and on the potential impact of DOTS on amplification of resistance are limited. Therefore, we analyzed treatment results from a cross-sectional sample of patients with TB enrolled in a DOTS program in an area with high levels of drug resistance in Uzbekistan and Turkmenistan in Central Asia. METHODS: Sputum samples for testing for susceptibility to 5 first-line drugs and for molecular typing were obtained from patients starting treatment in 8 districts. Patients with sputum smear results positive for TB at the end of the intensive phase of treatment and/or at 2 months into the continuation phase were tested again. RESULTS. Among 382 patients with diagnoses of TB, 62 did not respond well to treatment and were found to be infected with an identical Mycobacterium tuberculosis strain when tested again; 19 of these patients had strains that developed new or additional drug resistance. Amplification occurred in only 1.2% of patients with initially susceptible or monoresistant TB strains, but it occurred in 17% of those with polyresistant strains (but not multidrug-resistant strains, defined as strains with resistance to at least isoniazid and rifampicin) and in 7% of those with multidrug-resistant strains at diagnosis. Overall, 3.5% of the patients not initially infected with multidrug-resistant TB strains developed such strains during treatment. Amplification of resistance, however, was found only in polyresistant Beijing genotype strains. CONCLUSIONS: High levels of amplification of drug resistance demonstrated under well-established DOTS program conditions reinforce the need for implementation of DOTS-Plus for multidrug-resistant TB in areas with high levels of drug resistance. The strong association of Beijing genotype and amplification in situations of preexisting resistance is striking and may underlie the strong association between this genotype and drug resistance
Identifying the target genes of SUPPRESSOR OF GAMMA RESPONSE 1, a master transcription factor controlling DNA damage response in Arabidopsis
In mammalian cells, the transcription factor p53 plays a crucial role in transmitting DNA damage signals to maintain genome integrity. However, in plants, orthologous genes for p53 and checkpoint proteins are absent. Instead, the plant-specific transcription factor SUPPRESSOR OF GAMMA RADIATION 1 (SOG1) controls most of the genes induced by gamma irradiation and promotes DNA repair, cell cycle arrest, and stem cell death. Thus far, the genes directly controlled by SOG1 remain largely unknown, limiting the understanding of DNA damage signaling in plants. Here, we conducted a microarray analysis and chromatin immunoprecipitation (ChIP)-sequencing, and identified 146 Arabidopsis genes as direct targets of SOG1. By using the ChIP-sequencing data, we extracted the palindromic motif [CTT(N)7AAG] as a consensus SOG1-binding sequence, which mediates target gene induction in response to DNA damage. Furthermore, DNA damage-triggered phosphorylation of SOG1 is required for efficient binding to SOG1-binding sequence. Comparison between SOG1 and p53 target genes showed that both transcription factors control genes responsible for cell cycle regulation, such as CDK inhibitors, and DNA repair proteins, whereas SOG1 preferentially targets genes involved in homologous recombination. We also found that defense-related genes were enriched in the SOG1 target genes. Consistent with this, SOG1 is required for resistance against the hemi-biotrophic fungus Colletotrichum higginsianum, suggesting that SOG1 has a unique function in controlling immune response. This article is protected by copyright. All rights reserved
Recommended from our members
Thin film contamination effects on laser-induced damage of fused silica surfaces at 355 nm
Fused silica windows were artificially contaminated to estimate the resistance of target chamber debris shields against laser damage during NIF operation. Uniform contamination thin films (1 to 5 nm thick) were prepared by sputtering various materials (Au, Al, Cu, and B4C). The loss of transmission of the samples was first measured. They were then tested at 355 nm in air with an 8-ns Nd:YAG laser. The damage morphologies were characterized by Nomarski optical microscopy and SEM. Both theory and experiments showed that metal contamination for films as thin as 1 nm leads to a substantial loss of transmission. The laser damage resistance dropped very uniformly across the entire surface (e.g. 6 J/cm2 for 5 nm of Cu). The damage morphology characterization showed that contrary to clean silica, metal coated samples did not produce pits on the surface. B4C coated silica, on the other hand, led to a higher density of such damage pits. A model for light absorption in the thin film was coupled with a simple heat deposition and diffusion model to perform preliminary theoretical estimates of damage thresholds. The estimates of the loss due to light absorption and reflection pointed out significant .differences between metals (e.g. Al and Au). The damage threshold predictions were in qualitative agreement with experimental measurements
Epstein–Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis
We established two Epstein–Barr virus (EBV)-infected NKL sublines, which acquired stress resistant phenotype against DNA damage and starvation compared with EBV-negative NKL. EBV-rendered doxorubicin resistance at least partially through NF-κB activation and the resultant sustenance of antiapoptotic proteins including Bcl-XL and FLIPL/S
Drugs in early clinical development for the treatment of osteosarcoma
Introduction: Osteosarcomas are the main malignant primary bone tumours found in children
and young adults. Conventional treatment is based on diagnosis and resection surgery,
combined with polychemotherapy. This is a protocol that was established in the 1970s.
Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient
survival rate has not improved in the last four decades. New therapeutic approaches are thus
required to improve the prognosis for osteosarcoma patients.
Areas covered: From the databases available and published scientific literature, the present
review gives an overview of the drugs currently in early clinical development for the
treatment of osteosarcoma. For each drug, a short description is given of the relevant
scientific data supporting its development.
Expert opinion: Multidrug targeted approaches are set to emerge, given the heterogeneity of
osteosarcoma subtypes and the multitude of therapeutic responses. The key role played by the
microenvironment in the disease increases the number of therapeutic targets (such as
macrophages or osteoclasts), as well as the master proteins that control cell proliferation or
cell death. Ongoing phase I/II trials are important steps, not only for identifying new therapies
with greater safety and efficacy, but also for better defining the role played by the
microenvironment in the pathogenesis of osteosarcoma
- …